PRETRIAL ORDER NO. 77 THAT THE CASES LISTED IN APPENDIX A SHALL BE PLACED IN CIVIL SUSPENSE FOR STATISTICAL PURPOSES UNTIL FURTHER ORDER OF THE COURT.. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 2/21/2019. 2/22/2019 ENTERED AND COPIES E-MAILED TO LIAISON COUNSEL. (SEE DOCKET NO 874 IN 16-MD-2724)(kp, )
ORDER THAT THE CLAIMS OF OMITTED PLAINTIFFS IN THE INDIVIDUAL CASES LISTED IN APPENDIX A ARE VOLUNTARILY DISMISSED WITHOUT PREJUDICE PURSUANT TO F.R.C.P. 41(a)(1)(A)(ii); ALL CLAIMS AGAINST THE OMITTED DEFENDANTS WITH RESPECT TO THE PHARMACEUTICAL PRODUCT(S) AT ISSUE IN THE CASES LISTED IN APPENDIX B ARE VOLUNTARILY DISMISSED WITHOUT PREJUDICE PURSUANT TO F.R.C.P. 41(a)(1)(A)(ii); THIS ORDER SHALL HAVE NO EFFECT ON ANY TOLLING AGREEMENTS EXECUTED PRIOR TO THE DATE OF THIS ORDER, ETC. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 2/22/2018; 2/22/2018 ENTERED AND COPIES E-MAILED TO LIAISON COUNSEL. (SEE PAPER # 569 IN 16-MD-2724). (tjd)
ORDER THAT THE ATTACHED STIPULATION TO SET DEADLINES FOR RESPONSIVE PLEADINGS IS APPROVED. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 4/26/2017. 4/27/2017 ENTERED AND COPIES MAILED AND E-MAILED TO LIAISON COUNSEL. (SEE PAPER # 264 IN 16-MD-2724) (ems)
MOTION to Stay filed by ACTAVIS HOLDCO U.S., INC., FOUGERA PHARMACEUTICALS, INC., PERRIGO COMPANY PLC, PERRIGO NEW YORK, INC., SANDOZ, INC., SUN PHARMACEUTICAL INDUSTRIES LTD., TARO PHARMACEUTICAL INDUSTRIES, LTD., TARO PHARMACEUTICALS USA, INC..Memorandum. (Attachments: # 1 Memorandum, # 2 Text of Proposed Order)(SWAYZE, WALTER)
PRETRIAL ORDER NO. 12 THAT THE ABOVE-CAPTIONED CASES, ALREADY ASSIGNED TO THIS COURT'S CALENDAR, SHALL BE MADE PART OF IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION, 16-MD-2724, FOR COORDINATED AND CONSOLIDATED PRETRIAL PROCEEDINGS. IT IS FURTHER ORDERED THAT, EFFECTIVE THIS DATE, ALL CASES THAT ARE FILED DIRECTLY INTO THE MDL PURSUANT TO PRETRIAL ORDER NO. 1 SHALL LIST ON THE CIVIL COVER SHEET WITH THE RELATED CASE DESIGNATION THE GENERIC DRUG(S) UPON WHICH SUIT IS BROUGHT. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 4/10/2017. 4/11/2017 ENTERED AND COPIES MAILED AND E-MAILED TO LIAISON COUNSEL. (SEE PAPER # 195 IN 16-MD-2724) (ems)
ORDER GRANTING 19 PRO HAC VICE ADMISSION TO CHRISTOPHER T. HOLDING. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 2/8/17. 2/9/17 ENTERED AND COPIES E-MAILED. (va, )
STIPULATION AND ORDER TO SET DEADLINES FOR RESPONSIVE PLEADINGS. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 2/7/17. 2/8/17 ENTERED AND COPIES E-MAILED. (va, )
Disclosure Statement Form pursuant to FRCP 7.1 including Teva Pharmaceuticals USA, Inc., which is an indirect wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. with Certificate of Service by ACTAVIS HOLDCO U.S., INC..(LEVINE, JAN)
ORDER THAT THE APPLICATION OF LAURA SHORES, ESQ. TO PRACTICE IN THIS COURT PURSUANT TO LRCP 83.5.2(B) (PRO HAC VICE) ON BEHALF OF FOUGERA PHARMACEUTICALS, INC., SANDOZ, INC. IS GRANTED. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 2/2/17. 2/2/17 ENTERED AND COPIES MAILED, E-MAILED.(fdc)
ORDER THAT THE APPLICATION OF MARGARET ROGERS, ESQ. TO PRACTICE IN THIS COURT PURSUANT TO LRCP 83.5.2(B) (PRO HAC VICE) ON BEHALF OF FOUGERA PHARMACEUTICALS, INC., SANDOZ, INC. IS GRANTED. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 2/2/17. 2/2/17 ENTERED AND COPIES MAILED, E-MAILED.(fdc)
ORDER THAT THE APPLICATION OF SAUL P. MORGENSTERN, ESQ. TO PRACTICE IN THIS COURT PURSUANT TO LRCP 83.5.2(B) (PRO HAC VICE) ON BEHALF OF FOUGERA PHARMACEUTICALS, INC., SANDOZ, INC. IS GRANTED. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 2/2/17. 2/2/17 ENTERED AND COPIES MAILED, E-MAILED.(fdc)
APPLICATION for Admission Pro Hac Vice of LAURA SHORES by FOUGERA PHARMACEUTICALS, INC., SANDOZ, INC.. CERTIFICATE OF SERVICE. (FEE PAID ON 1/30/17). (va, )
APPLICATION for Admission Pro Hac Vice of MARGARET ROGERS by FOUGERA PHARMACEUTICALS, INC., SANDOZ, INC.. CERTIFICATE OF SERVICE. (FEE PAID ON 1/30/17). (va, )
APPLICATION for Admission Pro Hac Vice of SAUL P. MORGENSTERN by FOUGERA PHARMACEUTICALS, INC., SANDOZ, INC.. CERTIFICATE OF SERVICE. (FEE PAID ON 1/30/17) (va, )
ORDER THAT AS THESE CASES DO NOT ALLEGE ANTITRUST VIOLATIONS WITH REGARD TO GENERIC DIGOXIN OR DOXYCYCLINE, THEY ARE NOT PROPERLY FILED IN MDL 2724 AS PRESENTLY CONSTRUCTED. THEREFORE, THE CLERK IS DIRECTED TO REMOVE THE MDL 2724 DESIGNATION FROM THESE CASES PENDING A DECISION BY THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION ("JPML") WITH REGARD TO THE MOTION OF PLAINTIFF ROCHESTER DRUG COOPERATIVE FOR TRANSFER OF RELATED ACTIONS. IT IS FURTHER ORDERED THAT FOR PURPOSES OF JUDICIAL ADMINISTRATION, THE ABOVE-CAPTIONED CASES SHALL BE MARKED AS RELATED TO THE FIRST CASE FILED IN THIS COURT AS PART OF THE MDL, INTERNATIONAL UNION OF OPERATING ENGINEERS LOCAL 30 BENEFITS FUND v. LANNETT COMPANY, INC., CIVIL ACTION NO. 16-990, AND REMAIN AS PRESENTLY ASSIGNED PENDING FURTHER ORDER OF THIS COURT OR THE JPML. SIGNED BY HONORABLE CYNTHIA M. RUFE ON 1/3/2017. 1/3/2017 ENTERED AND COPIES MAILED AND E-MAILED TO LIAISON COUNSEL. (SEE PAPER # 101 IN 16-MD-2724) (ems)
DEMAND for Trial by Jury by ROCHESTER DRUG CO-OPERATIVE, INC.. (rt)
Filed: 12/27/2016, Entered: 12/28/2016
Summons Issued as to ACTAVIS HOLDCO U.S., INC., FOUGERA PHARMACEUTICALS, INC., PERRIGO COMPANY PLC, PERRIGO NEW YORK, INC., SANDOZ, INC., SUN PHARMACEUTICAL INDUSTRIES LTD., TARO PHARMACEUTICAL INDUSTRIES, LTD., TARO PHARMACEUTICALS USA, INC.. Eight Forwarded To: Counsel on December 28, 2016 (rt)
Update
Alerts
Jump